Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
164.45
+1.04 (0.64%)
Aug 10, 2026, 3:12 PM EDT - Market open
Neurocrine Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 332.4 | 713 | 233 | 251.1 | 262.9 | 340.8 |
Short-Term Investments | 57.4 | 767.4 | 843.1 | 780.5 | 726.4 | 370.5 |
Cash & Short-Term Investments | 389.8 | 1,480 | 1,076 | 1,032 | 989.3 | 711.3 |
Cash Growth | -60.05% | 37.57% | 4.31% | 4.28% | 39.08% | -11.20% |
Accounts Receivable | 887 | 686.8 | 479.1 | 439.3 | 350 | 185.5 |
Inventory | 104.2 | 69 | 57.4 | 38.3 | 35.1 | 30.5 |
Other Current Assets | 256.5 | 219.2 | 179.4 | 97.8 | 79.1 | 45.5 |
Total Current Assets | 1,638 | 2,523 | 1,725 | 1,607 | 1,454 | 972.8 |
Net Property, Plant & Equipment | 538.5 | 545.2 | 592 | 347.3 | 145.6 | 155.8 |
Other Intangible Assets | 2,226 | - | - | 35.5 | 37.2 | - |
Goodwill | 500.6 | - | - | - | - | - |
Long-Term Investments | 239.2 | 1,184 | 864.3 | 849.4 | 401.5 | 624.4 |
Other Long-Term Assets | 217.3 | 379.8 | 537.7 | 412.2 | 330.9 | 319.5 |
Total Assets | 5,359 | 4,632 | 3,719 | 3,251 | 2,369 | 2,073 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 808.3 | 674.3 | 461.6 | 448.8 | 347.6 | 225.8 |
Current Portion of Long-Term Debt | - | - | - | 170.1 | 169.4 | - |
Other Current Liabilities | 66.2 | 69.1 | 46.1 | 35.9 | 20.7 | 20 |
Total Current Liabilities | 874.5 | 743.4 | 507.7 | 654.8 | 537.7 | 245.8 |
Long-Term Debt | - | - | - | - | - | 335.1 |
Long-Term Leases | 401.8 | 415.3 | 455.1 | 258.3 | 93.5 | 105.3 |
Other Long-Term Liabilities | 389.2 | 219.7 | 166.2 | 106.3 | 29.7 | 12.3 |
Total Long-Term Liabilities | 791 | 635 | 621.3 | 364.6 | 123.2 | 452.7 |
Total Liabilities | 1,666 | 1,378 | 1,129 | 1,019 | 660.9 | 698.5 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Additional Paid-in Capital | 2,964 | 2,792 | 2,555 | 2,382 | 2,122 | 2,011 |
Accumulated Other Comprehensive Income | 5.1 | 13.1 | 5.8 | 7 | -7.9 | -1.7 |
Retained Earnings | 724 | 447.7 | 29.2 | -157.1 | -406.8 | -635.8 |
Shareholders' Equity | 3,694 | 3,253 | 2,590 | 2,232 | 1,708 | 1,374 |
Total Liabilities & Equity | 5,359 | 4,632 | 3,719 | 3,251 | 2,369 | 2,073 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 401.8 | 415.3 | 455.1 | 428.4 | 262.9 | 440.4 |
Net Cash (Debt) | -12 | 1,065 | 621 | 603.2 | 726.4 | 270.9 |
Net Cash Growth | - | 71.51% | 2.95% | -16.96% | 168.14% | -30.31% |
Net Cash Per Share | -0.12 | 10.39 | 5.99 | 5.97 | 7.34 | 2.77 |
Book Value | 3,694 | 3,253 | 2,590 | 2,232 | 1,708 | 1,374 |
Book Value Per Share | 35.70 | 31.74 | 24.97 | 22.10 | 17.27 | 14.03 |
Tangible Book Value | 967 | 3,253 | 2,590 | 2,197 | 1,671 | 1,374 |
Tangible Book Value Per Share | 9.35 | 31.74 | 24.97 | 21.75 | 16.89 | 14.03 |